Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications

Medical Principles and Practice

Volumn 25, Issue 2, 2016, Pages 60-72

  Rudokas, Mindaugas ^a   Najlah, Mohammad ^b   Alhnan, Mohamed Albed ^a   Elhissi, Abdelbary ^c  

^a UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^b ANGLIA RUSKIN UNIVERSITY   (United Kingdom)

^c Qatar University ^*  (Qatar)

Author keywords

Aerosol; Arikace; Formulation; Inhalation; Liposome; Lung

Indexed keywords

AMIKACIN; LIPOSOME; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CISPLATIN; DOXORUBICIN; DRUG CARRIER; MACROGOL DERIVATIVE;

CONFERENCE PAPER; DRUG CLASSIFICATION; DRUG FORMULATION; DRUG SAFETY; DRUG STABILITY; DRY POWDER INHALER; HUMAN; IN VIVO STUDY; LIPOSOMAL DELIVERY; LUNG CANCER; LUNG INFECTION; MEDICAL NEBULIZER; METERED DOSE INHALER; SOFT MIST INHALER; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; INHALATIONAL DRUG ADMINISTRATION; LUNG NEOPLASMS; PROCEDURES;

ADMINISTRATION, INHALATION; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CISPLATIN; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; LUNG NEOPLASMS; POLYETHYLENE GLYCOLS;

EID: 84961115733     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000445116     Document Type: Conference Paper

References (109)

1. American Cancer Society: Cancer facts and figures 2013. Atlanta. http://www.cancer.org/acs/groups/content/@ epidemiologysurveil-lance/documents/document/acspc-036845. pdf (accessed May 31, 2015).
2. Sihoe AD, Yim AP: Lung cancer staging. J Surg Res 2004; 117:92-106.
3. Senan S, Paul MA, Lagerwaard FJ: Treatment of early-stage lung cancer detected by screening: surgery or stereotactic ablative radiotherapy? Lancet Oncol 2013; 14:270-274.
4. Hu L, Liang G, Yuliang W, et al: Assessing the effectiveness and safety of liposomal paclitax-el in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial). Trials 2013; 14:45.
5. Kadam AN, Najlah M, Wan KW, et al: Stability of parenteral nanoemulsions loaded with paclitaxel: the influence of lipid phase composition, drug concentration and storage temperature. Pharm Dev Technol 2014; 19:999-1004.
6. Torchilin V: Passive and active drug targeting: drug delivery to tumors as an example; in Schäfer-Korting M (ed): Drug Delivery. Berlin, Springer, 2010, vol 197, pp 3-53.
7. Taylor KM, Taylor G, Kellaway IW, et al: The influence of liposomal encapsulation on sodium cromoglycate pharmacokinetics in man. Pharm Res 1989; 6:633-636.
8. Saari M, Vidgren MT, Koskinen MO, et al: Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers. Int J Pharm 1999; 181:1-9.
9. Clancy JP, Dupont L, Konstan MW, et al: Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013; 68:818-825.
10. Morimoto Y, Adachi Y: Pulmonary uptake of liposomal phosphatidylcholine upon intra-tracheal administration to rats. Chem Pharm Bull (Tokyo) 1982; 30:2248-2251.
11. Elhissi A, Ul Hassan I, Papapanou A, et al: Cationic liposomes as model nonviral vectors for pulmonary delivery of DNA; in Ale I, Chandrashekhar VK (eds): Advances in Planar Lipid Bilayers and Liposomes. Cambridge, Academic Press, 2014, vol 19, pp 53-66.
12. Jennings MT, Riekert KA, Boyle MP: Update on key emerging challenges in cystic fibrosis. Med Princ Pract 2014; 23:393-402.
13. Bannon A, Zhang SD, Schock BC, et al: Cystic fibrosis from laboratory to bedside: the role of a20 in NF-κB-mediated inflammation. Med Princ Pract 2015; 24:301-310.
14. Alton EWFW, Boyd AC, Porteous DJ, et al: A phase I/IIa safety and efficacy study of nebulized liposome-mediated gene therapy for cystic fibrosis supports a multidose trial. Am J Resp Crit Care Med 2015; 192:1389-1392.
15. Ehsan Z, Clancy JP: Management of Pseudo-monas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin. Future Mi-crobiol 2015; 10:1901-1912.
16. O'Callaghan C, Barry PW: The science of nebulised drug delivery. Thorax 1997; 52(suppl 2):S31-S44.
17. Elhissi AMA, Dennison SR, Ahmed W, et al: New delivery systems-liposomes for pulmonary delivery of antibacterial drugs; in Phoenix DA, Frederick H, Dennison SR (eds): Novel Antimicrobial Agents and Strategies. Weinheim, Wiley-VCH, 2014, pp 387-406.
18. Bangham AD, Standish MM, Watkins JC: Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13: 238-252.
19. Kirby CJ, Gregoriadis G: Liposomes; in Ma-thiowitz E (ed): Encyclopaedia of Controlled Drug Delivery. New York, Wiley, 1999, pp 461-492.
20. Hope MJ, Bally MB, Webb G, et al: Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 1985; 812:55-65.
21. Szoka F Jr, Papahadjopoulos D: Procedure for the preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA 1978; 75:4194-4198.
22. Perrett S, Golding M, Williams WP: A simple method for the preparation of liposomes for pharmaceutical applications: characterization of the liposomes. J Pharm Pharmacol 1991; 43:154-161.
23. Paul S, Rao S, Kohan R, et al: Poractant alfa versus beractant for respiratory distress syndrome in preterm infants: a retrospective cohort study. J Paediatr Child Health 2013; 49: 839-844.
24. Myers MA, Thomas DA, Straub L, et al: Pulmonary effects of chronic exposure to lipo-some aerosols in mice. Exp Lung Res 1993; 19: 1-19.
25. Schreier H, McNicol KJ, Ausborn M, et al: Pulmonary delivery of amikacin liposomes and acute liposome toxicity in the sheep. Int J Pharm 1992; 87:183-193.
26. Canonico AE, Plitman JD, Conary JT, et al: No lung toxicity after repeated aerosol or intravenous delivery of plasmid-cationic lipo-some complexes. J Appl Physiol (1985) 1994; 77:415-419.
27. Waldrep JC, Scherer PW, Hess GD, et al: Nebulized glucocortecoids in liposomes: aerosol characteristics and human dose estimates J Aerosol Med 1994; 7:135-145.
28. Gilbert BE, Knight C, Alvarez FG, et al: Tolerance of volunteers to cyclosporine a-dilauro-ylphosphatidylcholine liposome aerosol. Am J Respir Crit Care Med 1997; 156:1789-1793.
29. Khanna C, Anderson PM, Hasz DE, et al: In-terleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 1997; 79: 1409-1421.
30. Ten RM, Anderson PM, Zein NN, et al: Inter-leukin-2 liposomes for primary immune deficiency using the aerosol route. Int Immuno-pharmacol 2002; 2:333-344.
31. Skubitz KM, Anderson PM: Inhalational in-terleukin-2 liposomes for pulmonary metas-tases: a phase I clinical trial. Anticancer Drug 2000; 11:555-563.
32. Verschraegen CF, Gilbert BE, Loyer E, et al: Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(S)-camp-tothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 2004; 10: 2319-2326.
33. Jendle J, Karlberg BE, Persliden J, et al: Delivery and retention of an insulin aerosol produced by a new jet nebulizer. J Aerosol Med 1995; 8:243-254.
34. Parthasarathy R, Gilbert B, Mehta K: Aerosol delivery of liposomal all-trans-retinoic acid to the lungs. Cancer Chemother Pharmacol 1999; 43:277-283.
35. Knight V, Gilbert B: Antiviral therapy with small particle aerosols. Eur J Clin Microbiol Infect Dis 1988; 7:721-731.
36. Corcoran TE, Venkataramanan R, Mihelc KM, et al: Aerosol deposition of lipid complex am-photericin-B (Abelcet) in lung transplant recipients. Am J Transplant 2006; 6: 2765-2773.
37. Monforte V, Lopez-Sanchez A, Zurbano F, et al: Prophylaxis with nebulized liposomal am-photericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant. J Heart Lung Transplant 2013; 32:313-319.
38. Farr SJ, Kellaway IW, Carman-Meakin B: Assessing the potential of aerosol-generated li-posomes from pressurised pack formulations. J Control Release 1987; 5:119-127.
39. Vyas SP, Sakthivel T: Pressurized pack-based liposomes for pulmonary targeting of iso-prenaline-development and characterization. J Microencapsul 1994; 11:373-380.
40. Alouache AI, Kellaway IW, Taylor KMG, et al: Stability kinetics of HFA suspensions prepared with a fluoroalcohol and PEG-phos-pholipids. J Aerosol Med 2006; 20:373.
41. Radhakrishnan R, Mihalko PJ, Abra RM: Method and apparatus for administering dehydrated liposomes by inhalation. Google Patents US 4895719 A. 1990.
42. Lo Yl, Tsai JC, Kuo JH: Liposomes and disac-charides as carriers in spray-dried powder formulations of superoxide dismutase. J Control Release 2004; 94:259-272.
43. Ourique AF, Chaves Pdos S, Souto GD, et al: Redispersible liposomal-N-acetylcysteine powder for pulmonary administration: development, in vitro characterization and antioxidant activity. Eur J Pharm Sci 2014; 65: 174-182.
44. Seville PC, Kellaway IW, Birchall JC: Preparation of dry powder dispersions for non-viral gene delivery by freeze-drying and spray-drying. J Gene Med 2002; 4:428-437.
45. Payne NI, Browning I, Hynes CA: Characterization of proliposomes. J Pharm Sci 1986; 75: 330-333.
46. Payne NI, Timmins P, Ambrose CV, et al: Proliposomes: a novel solution to an old problem. J Pharm Sci 1986; 75:325-329.
47. Alves GP, Santana MHA: Phospholipid dry powders produced by spray drying processing: structural, thermodynamic and physical properties. Powder Technol 2004; 145:139-148.
48. Rojanarat W, Changsan N, Tawithong E, et al: Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies. Int J Mol Sci 2011; 12:4414-4434.
49. Hindle M: Soft Mist Inhalers: A Review of Current Technology: Drug Delivery Companies Report. Oxford, Autumn/Winter, 2004, pp 31-34.
50. Elhissi A, Ahmed W: Advances in design and technology of devices manufactured for drug delivery applications; in Jackson M, Davim JP (eds): Medical Device Manufacturing. New York, Nova, 2011.
51. ® soft mist inhaler and seven pressurized metered dose inhalers. Allergol Int 2015; 64:390-392.
52. Deshpande D, Blanchard J, Srinivasan S, et al: Aerosolization of lipoplexes using AERx Pulmonary Delivery System. AAPS PharmSci 2002; 4:1-10.
53. ® Pulmonary Delivery System. Respir Drug Delivery IX 2004: 353-355.
54. Ari A, Atalay OT, Harwood R, et al: Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. Respir Care 2010; 55:845-851.
55. Ehsan Z, Wetzel JD, Clancy JP: Nebulized li-posomal amikacin for the treatment of pseu-domonas aeruginosa infection in cystic fibro-sis patients. Expert Opin Investig Drugs 2014; 23:743-749.
56. Loira-Pastoriza C, Todoroff J, Vanbever R: Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev 2014; 75:81-91.
57. Bridges PA, Taylor KMG: Nebulisers for the generation of liposomal aerosols. Int J Pharm 1998; 173:117-125.
58. Elhissi AMA, Taylor KMG: Delivery of lipo-somes generated from proliposomes using air-jet, ultrasonic, and vibrating-mesh nebu-lisers. J Drug Deliv Sci Tech 2005; 15:261-265.
59. Elhissi AM, Ahmed W, Taylor KM: Laser diffraction and electron microscopy studies on inhalable liposomes generated from particu-late-based proliposomes within a medical nebulizer. J Nanosci Nanotechnol 2012; 12: 6693-6699.
60. Lehofer B, Bloder F, Jain PP, et al: Impact of atomization technique on the stability and transport efficiency of nebulized liposomes harboring different surface characteristics. Eur J Pharm Biopharm 2014; 88:1076-1085.
61. Leung KKM, Bridges PA, Taylor KMG: The stability of liposomes to ultrasonic nebulisa-tion. Int J Pharm 1996; 145:95-102.
62. Elhissi AM, Faizi M, Naji WF, et al: Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int J Pharm 2007; 334:62-70.
63. Cipolla D, Wu H, Gonda I, et al: Aerosol performance and long-term stability of surfactant-associated liposomal ciprofloxacin formulations with modified encapsulation and release properties. AAPS PharmSciTech 2014; 15:1218-1227.
64. Taylor KMG, McCallion ONM: Ultrasonic nebulisers for pulmonary drug delivery. Int J Pharm 1997; 153:93-104.
65. Dhand R: Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 2002; 47:1406-1416; discussion 1416-1408.
66. Taylor KMG, Taylor G, Kellaway IW, et al: The stability of liposomes to nebulisation. Int J Pharm 1990; 58:57-61.
67. Niven RW, Schreier H: Nebulization of lipo-somes. I. Effects of lipid composition. Pharm Res 1990; 7:1127-1133.
68. Desai TR, Hancock RE, Finlay WH: A facile method of delivery of liposomes by nebuliza-tion. J Control Release 2002; 84:69-78.
69. Bruinenberg P, Blanchard JD, Cipolla DC, et al: Inhaled liposomal ciprofloxacin: once a day management of respiratory infections. Respir Drug Delivery IX 2010; 1:73-82.
70. Elhissi A, Gill H, Ahmed W, et al: Vibrating-mesh nebulization of liposomes generated using an ethanol-based proliposome technology. J Liposome Res 2011; 21:173-180.
71. Kamalaporn H, Leung K, Nagel M, et al: Aerosolized liposomal amphotericin B: a potential prophylaxis of invasive pulmonary as-pergillosis in immunocompromised patients. Pediatr Pulmonol 2014; 49:574-580.
72. Udhrain A, Skubitz KM, Northfelt DW: Pe-gylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma. Int J Nanomedicine 2007; 2:345-352.
73. Green AE, Rose PG: Pegylated liposomal doxorubicin in ovarian cancer. Int J Nano-medicine 2006; 1:229-239.
74. Konduri KS, Nandedkar S, Rickaby DA, et al: The use of sterically stabilized liposomes to treat asthma. Methods Enzymol 2005; 391: 413-427.
75. Konduri KS, Nandedkar S, Duzgunes N, et al: Efficacy of liposomal budesonide in experimental asthma. J Allergy Clin Immunol 2003; 111:321-327.
76. Gautam A, Waldrep JC, Densmore CL, et al: Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of P53 gene and 9-nitrocamptothecin. Gene Ther 2002; 9:353-357.
77. National Institute for Health and Clinical Excellence (NICE): Lung cancer: diagnosis and management. NICE guidelines CG121. 2011. http://www.nice.org.uk/nicemedia/live/13465/54202/54202.pdf (accessed May 31, 2015).
78. Zhou J, Zhao WY, Ma X, et al: The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials 2013; 34:3626-3638.
79. Minchinton AI, Tannock IF: Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583-592.
80. Koshkina NV, Waldrep JC, Roberts LE, et al: Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in mu-rine renal carcinoma model. Clin Cancer Res 2001; 7:3258-3262.
81. Garbuzenko OB, Saad M, Betigeri S, et al: In-tratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm Res 2009; 26: 382-394.
82. Hitzman CJ, Wattenberg LW, Wiedmann TS: Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lip-id-coated nanoparticles. J Pharm Sci 2006; 95: 1196-1211.
83. Antony GK, Dudek AZ: Interleukin 2 in cancer therapy. Curr Med Chem 2010; 17: 3297-3302.
84. Khanna C, Hasz DE, Klausner JS, et al: Aerosol delivery of interleukin 2 liposomes is non-toxic and biologically effective: canine studies. Clin Cancer Res 1996; 2:721-734.
85. Posch C, Weihsengruber F, Bartsch K, et al: Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. Br J Cancer 2014; 110:1427-1432.
86. Wittgen BP, Kunst PW, van der Born K, et al: Phase I study of aerosolized slit cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res 2007; 13:2414-2421.
87. 2-enriched air: pharmacokinetic studies. Cancer Chemother Pharmacol 2001; 47:451-456.
88. Chen J, Ping QN, Guo JX, et al: Effect of phos-pholipid composition on characterization of liposomes containing 9-nitrocamptothecin. Drug Dev Ind Pharm 2006; 32:719-726.
89. Knight V, Kleinerman ES, Waldrep JC, et al: 9-nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xeno-grafts and pulmonary cancer metastases in mice. Ann NY Acad Sci 2000; 922:151-163.
90. Knight V, Koshkina NV, Waldrep JC, et al: Anticancer effect of 9-nitrocamptothecin li-posome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol 1999; 44:177-186.
91. Koshkina NV, Kleinerman ES, Waidrep C, et al: 9-nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 2000; 6:2876-2880.
92. Tedesco KL, Berlin J, Rothenberg M, et al: A phase I study of concurrent 9-nitro-20(S)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. Ra-diother Oncol 2005; 76:54-58.
93. Lawson KA, Anderson K, Snyder RM, et al: Novel vitamin E analogue and 9-nitro-camp-tothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis. Cancer Che-mother Pharmacol 2004; 54:421-431.
94. Rich TA, Winter K, Safran H, et al: Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl trans-ferase inhibitor R115777 for locally advanced pancreatic cancer. Onco Targets Ther 2012; 5: 161-170.
95. Ghazanfari T, Elhissi AM, Ding Z, et al: The influence of fluid physicochemical properties on vibrating-mesh nebulization. Int J Pharm 2007; 339:103-111.
96. Najlah M, Vali A, Taylor M, et al: A study of the effects of sodium halides on the performance of air-jet and vibrating-mesh nebulizers. Int J Pharm 2013; 456:520-527.
97. Saari SM, Vidgren MT, Herrala J, et al: Possibilities of formoterol to enhance the peripheral lung deposition of the inhaled liposome corti-costeroids. Respir Med 2002; 96: 999-1005.
98. 99mTc-labeled beclomethasone-DLPC lipo-somes in mild and severe asthma. Chest 1998; 113:1573-1579.
99. Batavia R, Taylor KM, Craig DQ, et al: The measurement of beclomethasone dipropio-nate entrapment in liposomes: a comparison of a microscope and an HPLC method. Int J Pharm 2001; 212:109-119.
100. Khan I, Yousaf S, Subramanian S, et al: Pro-liposome powders prepared using a slurry method for the generation of beclometa-sone dipropionate liposomes. Int J Pharm 2015; 496:342-350.
101. Guan P, Lu Y, Qi J, et al: Solidification of liposomes by freeze-drying: the importance of incorporating gelatin as interior support on enhanced physical stability. Int J Pharm 2015; 478:655-664.
102. Koshkina NV, Golunski E, Roberts LE, et al: Cyclosporin A aerosol improves the anti-cancer effect of paclitaxel aerosol in mice. J Aerosol Med 2004; 17:7-14.
103. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the mul-tidrug transporter. Annu Rev Biochem 1993; 62:385-427.
104. Garbuzenko OB, Saad M, Pozharov VP, et al: Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oli-gonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci USA 2010; 107: 10737-10742.
105. Hsia TC, Lin CC, Wang JJ, et al: Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression. Lung 2002; 180:173-179.
106. Garbuzenko OB, Mainelis G, Taratula O, et al: Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention. Cancer Biol Med 2014; 11: 44-55.
107. Gaspar MM, Radomska A, Gobbo OL, et al: Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats. J Aerosol Med Pulm Drug Deliv 2012; 25:310-318.
108. Verschraegen CF, Gilbert BE, Huaringa AJ, et al: Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs. Ann NY Acad Sci 2000; 922:352-354.
109. Koshkina NV, Gilbert BE, Waldrep JC, et al: Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Che-mother Pharmacol 1999; 44:187-192.